A Stanford-led study has uncovered why certain diabetes patients fail to respond to blockbuster GLP-1 drugs like Ozempic, even when the medications work wonders for most others. The culprit appears to be a genetic quirk that forces the body to pump out extra hormone while simultaneously ignoring it.
Roughly one in ten people carry genetic variants that trigger this paradoxical resistance. They produce higher-than-normal levels of GLP-1, the hormone that regulates blood sugar, yet their bodies refuse to listen. After six months of treatment with GLP-1 receptor agonists, only 11.5% of patients with one variant hit their blood sugar targets, compared to 25% of those without the genetic hiccup.
The research, published in Genome Medicine and conducted over a decade by scientists from Stanford Medicine, ETH Zurich, and institutions across four continents, focused on variants in a gene called PAM. This enzyme plays a peculiar role: it's the only one in the human body capable of a chemical process that stabilizes and strengthens various hormones, including GLP-1.
Anna Gloyn, a Stanford genetics professor and senior author, described the findings as unexpected. "What we actually saw was they had increased levels of GLP-1," she said. "This was the opposite of what we imagined we would find." Despite the surplus hormone, resistant patients saw no benefit. More GLP-1 was needed to produce the same biological effect.
The team verified the discovery through years of additional testing, including experiments in mice engineered to lack the PAM gene. Those animals displayed identical resistance patterns: elevated GLP-1 levels but blunted response to the hormone. Mice without PAM also failed to show the typical GLP-1 effect of slowing stomach emptying, a key mechanism behind both blood sugar control and weight loss.
The exact mechanism remains a mystery. "That is the million-dollar question," Gloyn admitted. "We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about. No matter what we've done, we've not been able to nail precisely why they are resistant." The resistance appears to operate somewhere downstream in the biological pathway, after GLP-1 binds to its receptor.
The implications for treatment are significant. More than one-quarter of Type 2 diabetes patients now take GLP-1 receptor agonists, making this a widespread problem. Early identification of resistant patients could spare them months of failed treatment and accelerate the move toward personalized medicine. Mahesh Umapathysivam, one of the study's lead authors, noted the clinical frustration. "I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically," he said from Adelaide University. "This is the first step in being able to use someone's genetic make-up to help us improve that decision-making process."
The resistance proved specific to GLP-1 drugs. Patients with PAM variants responded normally to other diabetes medications like metformin and sulfonylureas, suggesting the problem is unique to how GLP-1 receptor agonists work.
Weight loss remains an open question. Ozempic and Wegovy use much higher doses for obesity treatment than for diabetes control, and the available data on weight loss outcomes was too limited to draw firm conclusions. Gloyn hopes pharmaceutical companies will mine their genetic databases to uncover whether similar variants explain poor weight loss responses.
Long-acting GLP-1 formulations may be better equipped to overcome resistance, based on preliminary evidence. Gloyn also suggests that treatments similar to insulin sensitizers, which help people respond better to insulin, could eventually be developed to sensitize patients to GLP-1.
Author Jessica Williams: "This discovery transforms a frustrating clinical mystery into actionable science, but the stubborn question of exactly why resistance happens remains maddeningly elusive."
Comments